Antioxidant activity of Trolox derivatives toward methylperoxyl radicals: thermodynamic and kinetic theoretical study

Saїd, Anes El-hadj; Mekelleche, Sidi Mohamed

doi:10.1007/s00214-021-02815-z

Cited by 4 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…/k exp. ratio was estimated to be about 1–2.9 and has also been successfully used by other authors. − Solvation model density (SMD) method was utilized to examine the effect of pentylethanoate and water medium on the antioxidant’s antiradical capability . The rate constants were calculated using the QM-ORSA (quantum mechanics-based test for overall free radical scavenging activity) technique. , Table S1 given in the Supporting Information (SI) describes the procedure in further detail.…”

Section: Methodsmentioning

confidence: 99%

Exploring the Multitarget Activity of Wedelolactone against Alzheimer’s Disease: Insights from In Silico Study

et al. 2023

View full text Add to dashboard Cite

In this study, Wedelolactone's multitarget activity against Alzheimer's disease was examined using density functional theory and molecular docking techniques. At physiological pH, the pK a and molar fractions have been estimated. The most likely relative rate constants of two radical scavenger mechanisms are formal hydrogen transfer in a lipid environment and single-electron transfer in a water solvent. Compared to Trolox (k overall = 8.96 × 10 4 M −1 s −1 ), Wedelolactone (k overall = 4.26 × 10 9 M −1 s −1 ) is more efficient in scavenging the HOO • radical in an aqueous environment. The chelation capacity of metals was investigated by examining the complexation of the Cu(II) ion at various coordination positions and calculating the complexation kinetic constants. Furthermore, molecular docking simulations showed that the known forms of Wedelolactone at physiological pH effectively inhibited the AChE and BChE enzymes by comparing their activity to that of tacrine (control). Wedelolactone is a promising drug candidate for Alzheimer's disease therapy in light of these findings.

show abstract